Study wrapper · #681
Synthetic Adrenocorticotropic Peptides Modulate the Expression Pattern of Immune Genes in Rat Brain following the Early Post-Stroke Period.
Editor's note
Part of the same transcriptomic program, this study profiled Semax and ACTH(6-9)PGP in a rat stroke model at the earlier 4.5-hour timepoint, within the therapeutic window the authors care about. Using RNA-seq they found 131 (Semax) and 322 (related peptide) differentially expressed genes and reported that both peptides partly offset ischemia-driven changes in immune- and neurosignaling-related genes, with peptide-specific differences among immune genes. As mechanistic preclinical work it helps map the timing of Semax's molecular effects, relevant to when a neuroprotective agent would need to act. It carries the same caveats: single lab, single model, gene-level endpoints only. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
The first few hours after a stroke are a critical window for treatment. This rat study looked at gene activity in the frontal cortex just 4.5 hours after a temporary stroke, comparing untreated animals with those given Semax or a related peptide. Semax changed about 131 genes and the related peptide about 322. Both peptides partly reversed the stroke-driven changes in genes controlling immune responses and nerve-cell signaling, though they differed in which immune genes they affected. The researchers highlight this early time point because that is when a protective drug would need to work. This is laboratory gene-analysis in rats designed to understand how these peptides act and when; it is not a test of Semax as a stroke treatment in people, and it reports no clinical or behavioral outcomes.